SynthesisPathology oncology research : POR2022
Pathological Diagnosis, Work-Up and Reporting of Breast Cancer 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.
Synthesis in Pathology oncology research : POR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiotherapy of Breast Cancer-Professional Guideline 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.Pathology oncology research : POR · 2022Pooled it
- Article
- Natural language processing for local, regional, and distant breast cancer relapse identification in pathology reports.Breast cancer research and treatment · 2025Article
- [Pathological diagnosis, work-up and reporting of breast cancer. Recommendations of the 5th Hungarian Consensus Conference on Breast Cancer].Magyar onkologia · 2025Article
- Improving diagnostic standards: a two-cycle clinical audit on core biopsy reports adherence to international guidelines for breast lesions.Annals of medicine and surgery (2012) · 2025Article
- A Low-Cost Optomechatronic Diffuse Optical Mammography System for 3D Image Reconstruction: Proof of Concept.Diagnostics (Basel, Switzerland) · 2025Article
- Glucocorticoid Receptor Isoforms in Breast Cancer Raise Implications for Personalised Supportive Therapies.International journal of molecular sciences · 2024Article
- Combining Molecular and Traditional Prognostic Factors: A Holistic Approach to Breast Cancer Prognostication.Diagnostics (Basel, Switzerland) · 2024Article
- Pathology and resection margins following mastectomy prior to immediate breast reconstruction.Gland surgery · 2024Review
- Article
- Unravelling heterogeneous effects of cancer‑associated fibroblasts on poor prognosis markers in breast cancer EM‑G3 cell line:Oncology reports · 2024Article
- Article
- Modern Breast Cancer Surgery 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.Pathology oncology research : POR · 2022Article
- Use of Diagnostic Imaging Modalities in Modern Screening, Diagnostics and Management of Breast Tumours 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.Pathology oncology research : POR · 2022Review
- Breast Cancer Survivorship Programme: Follow-Up, Rehabilitation, Psychosocial Oncology Care. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.Pathology oncology research : POR · 2022Article
- Editorial: Guidelines From the Central-Eastern European Professional Consensus Statement on Breast Cancer.Pathology oncology research : POR · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This text is based on the recommendations accepted by the 4th Hungarian Consensus Conference on Breast Cancer, modified on the basis of the international consultation and conference within the frames of the Central-Eastern European Academy of Oncology. The recommendations cover non-operative, intraoperative and postoperative diagnostics, determination of prognostic and predictive markers and the content of cytology and histology reports. Furthermore, they address some specific issues such as the current status of multigene molecular markers, the role of pathologists in clinical trials and prerequisites for their involvement, and some remarks about the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.